E
Exosome Diagnostics
Biotech & Life Sciences · Waltham, United States · Founded 2008
Commercializing minimally invasive molecular diagnostics in blood and urine to enable doctors to select optimal therapies for cancer and other diseases MoreLess
Exosome Diagnostics, accessible via exosomedx.com, is a pioneering biotech company specializing in the early detection of diseases through innovative exosome-based tests. Exosomes are tiny particles released by cells that carry genetic information. By analyzing these particles, Exosome Diagnostics can identify disease markers at an early stage, particularly in prostate cancer.
The company's flagship product, the ExoDx Prostate Test, is a non-invasive urine test that detects three critical genomic biomarkers associated with high-grade prostate cancer. This test helps physicians determine whether a patient should undergo a diagnostic biopsy, potentially sparing many from unnecessary procedures. The test is included in the National Comprehensive Cancer Network (NCCN) guidelines, underscoring its clinical relevance and reliability.
Exosome Diagnostics primarily serves healthcare providers, including urologists and oncologists, who are looking for advanced diagnostic tools to improve patient outcomes. The company also collaborates with pharmaceutical firms to enhance their research capabilities using exosome technology.
Operating in the rapidly growing liquid biopsy market, Exosome Diagnostics employs a business model that combines direct sales of its diagnostic tests with partnerships in the pharmaceutical sector. Revenue is generated through the sale of these tests and collaborative research agreements.
The company is led by a team of experts, including Chief Scientific Officer Johan Skog, one of the first scientists to discover exosomes, and Scientific Director Michael, who has a lifelong passion for revolutionizing cancer treatment. Their expertise and vision are driving the company to the forefront of medical diagnostics.
In summary, Exosome Diagnostics is transforming the landscape of disease detection and patient care through its cutting-edge exosome-based technology.
Keywords: exosome, diagnostics, prostate cancer, urine test, biomarkers, liquid biopsy, early detection, healthcare, biotech, oncology.
Company overview
Exosome Diagnostics company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2008
- Headquarters
- Waltham, United States
- Employees
- 59
- Open positions
- None listed
- Dealroom signal
- 61.1
Valuation & funding
Exosome Diagnostics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Sep 2025 | $15M | — | MDxHealth | ↗ |
| ACQUISITIONOther financing | Aug 2018 | $0 | — | Bio-Techne | ↗ |
| SERIES COther financing | Jul 2017 | $30M | $120M | Blue Bridge Capital · Arcus Ventures · b2venture · NGN Capital | — |
| SERIES BOther financing | Jan 2016 | $16M | $64M | Undisclosed | — |
| SERIES BOther financing | Sep 2015 | $18M | $70M | Undisclosed | — |
| EARLY VCOther financing | Jul 2015 | Undisclosed | — | ||
| SERIES BOther financing | Mar 2014 | Forbion Capital Partners · Tiger Partners · Monashees · Qiagen | — | ||
| SERIES AOther financing | May 2010 | NGN Capital · Forbion Capital Partners | — | ||
| SPINOUTOther financing | Jan 2008 | Massachusetts Institute of Technology | — |
Growth signals
Exosome Diagnostics website traffic
Latest recorded traffic for Exosome Diagnostics is 1.1K monthly website visits, down 67.6% over the last three months. Exosome Diagnostics's team declined 15.7% over the past year.
Comparisons
Exosome Diagnostics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Exosome Diagnostics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Exosome Diagnostics has talent and traffic
team presence
In the news
Latest news about Exosome Diagnostics
Recent press, funding announcements, and product moves mentioning Exosome Diagnostics — open to read from the original sources.
Market sentiment
What the market is saying about Exosome Diagnostics
An AI-synthesized read of the highest-engagement posts about Exosome Diagnostics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Exosome Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.